PROLINE HDL-c direct FS
HDL-c direct FS is a homogenous block-polymer based assay for direct determination of high-density lipoprotein cholesterol (HDL-c) in serum and plasma. This lipoprotein class is characterized by a protective effect impeding atherosclerotic plaque formation. Thus, reduced HDL-c concentrations are associated with high risk of atherosclerotic heart disease.
Cholesterol is an essential component in the body, synthesized by cells and absorbed from food. It serves as a part of cell membranes and as a precursor for steroid hormones and bile acids. In plasma, cholesterol is transported by lipoproteins, which are complexes of lipids and apolipoproteins. There are four main types: HDL (high-density lipoprotein), LDL (low-density lipoprotein), VLDL (very low-density lipoprotein), and chylomicrons.
HDL-c (high-density lipoprotein cholesterol) plays a vital role in protecting the body by inhibiting the formation of atherosclerotic plaques in the arteries. HDL-c is also involved in the process of removing cholesterol from peripheral cells and body tissues, which is then transported to the liver for further processing. Additionally, HDL-c has antioxidant effects and acts as a mediator of inflammation and antithrombotic responses.
Low HDL-c levels are a major risk factor for coronary heart disease (CHD). A reduction in HDL-c, especially when combined with elevated triglycerides, can increase the risk of atherosclerosis and heart disease. Conversely, higher HDL-c levels tend to reduce the risk of cardiovascular disease, including CHD. Therefore, monitoring HDL-c levels is crucial for assessing cardiovascular risk, and a complete lipid profile, including HDL-c, is highly recommended in dyslipidemia screenings.
| HDL levels in the body increase during: | HDL levels in the body decrease during: |
| Hyper-β-Lipoproteinemia | Dyslipoproteinemia |
| Tangier Disease | |
| Atherosclerosis risk assessment |
Using a homogeneous method for measuring HDL cholesterol without the need for centrifugation steps (direct method).
- Liquid reagent, open-system, ready to use without the need for reconstitution.
- Reagent functionality and installation testing guarantee.
- Good performance in linearity and stability.
- Available in MPK (multi-purpose kit) and dedicated kit types.
| Sample type | Serum atau Plasma |
| Measurement range | 3 mg/dL - 200 mg/dL |
| Analysis wavelength | 578 nm |
| Analysis mode | End-Point |
| Reagent aspiration volume for manual instrument | R1: 1000 µL ; R2: 250 µL |
| Sample aspiration volume for manual instrument | 10 µL |
| Storage temperature | 2 – 8 °C |
| pH | R1: 6.85 |
| R2: 8.15 | |
| Odor characteristics | No spesific odor |
| Visual characteristics | R1: Transparant, no color until pink |
| R2: Transparan, much yellow, no color until pink | |
| On-board stability | 6 weeks |
| Expiration date | 24 months |
| Control for HDL Reagent | Calibrator for HDL Reagent |
| TruLab L Level 1 | TruCal Lipid |
| TruLab L Level 2 |
| Nomor Katalog | R1 Reagent Volume | R2 Reagent Volume |
| 1 3561 99 10 022 | 5 x 20 mL | 1 x 25 mL |
| 1 3561 99 10 025 | 3 x 80 mL | 1 x 60 mL |
| 1 3561 99 10 029 | 3 x 200 mL | 1 x 150 mL |
| 1 3561 99 10 920 | 4 x 38 mL | 4 x 11 mL |
| 1 3561 99 10 921 | 4 x 23 mL | 4 x 7 mL |
| 1 3561 99 10 191 | 4 x 36 mL | 4 x 9 mL |
| 1 3561 99 10 181 | 4 x 36 mL | 4 x 9 mL |
| Reference Range: | ||
| Low | <40 mg/dL | < 1,65 mmol/L |
| High | ≥60 mg/dL | ≥ 1,55 mmol/L |
| Interfering Substances | Interference ≤ 10% up to (mg/dL) | Analytical Concentration (mg/dL) |
| Ascorbate | 60 | 35 |
| 60 | 81 | |
| Conjugated Bilirubin | 40 | 38,8 |
| 40 | 79,4 | |
| Unconjugated Bilirubin | 60 | 42,7 |
| 60 | 80,7 | |
| Hemolysis | 800 | 31,2 |
| 1000 | 70,1 | |
| Lipemia (Triglycerides) | 1000 | 38,8 |
| N-acetylcysteine (NAC) | 1700 | 36,7 |
| 1700 | 74,3 |
- HDL-c direct reagent
- Doos
- Kit insert
- Reagents bottle
- Rifai N, Bachorik PS, Albers JJ. Lipids, lipoproteins and apolipoproteins. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: W.B Saunders Company; 1999. p. 809-61.
- Cole TG, Klotzsch SG, McNamara J. Measurement of triglyceride concentration. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of lipoprotein testing. Washington: AACC Press, 1997. p. 115-26.
- Recommendation of the Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998;19: 1434-503.Guder WG, Zawta B et al. The Quality of Diagnostic Samples. 1st ed. Darmstadt: GIT Verlag; 2001; p. 46-7.
- Young DS. Effects of Drugs on Clinical Laboratory Tests. 5th. ed. Volume 1 and 2. Washington, DC: The American Assoiation for Clinical Chemistry Press 2000.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007; 45(9):1240- 1243.
- Aterosklerosis
- Metabolisme Lipid
Hubungi tim kami untuk mengetahui lebih lanjut mengenai informasi produk dan pemesanan.
- Telp : +62-21-8984-2722
- WhatsApp : +62-815-1359-2626
- Email : marketing@proline.co.id
Hubungi tim bantuan Teknis kami untuk pertolongan lebih lanjut terkait spesifikasi produk, layanan, dan dokumen teknis lainnya.
- Telp : +62-21-8984-2722
- WhatsApp : +62-817-9324-884
- Email : technical.support@prodis.co.id